DRG Epidemiology’s coverage of osteopenia comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report the prevalence of…
DRG Epidemiology’s coverage of osteopenia comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report the prevalence of…
DRG Epidemiology’s coverage of osteopenia comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report the prevalence of…
Clarivate Epidemiology's coverage of erectile dysfunction comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States,…
DRG Epidemiology's coverage of OPE comprises epidemiological estimates of key patient populations across 14 mature and emerging pharmaceutical markets worldwide. We report the prevalence of…
The treatment landscape for COVID-19 continues to evolve rapidly. Even with vaccines having become available in the markets under study, intense ongoing research has also focused on approaches…
Clarivate Epidemiology's coverage of BRAF comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany,…
DRG Epidemiology’s coverage of epilepsy comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of epilepsy for each…
DRG Epidemiology’s coverage of epilepsy comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of epilepsy for each…
DRG Epidemiology’s coverage of epilepsy comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of epilepsy for each…
DRG Epidemiology’s coverage of epilepsy comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of epilepsy for each…
DRG Epidemiology’s coverage of epilepsy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain…
DRG Epidemiology’s coverage of epilepsy comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of epilepsy for each…
DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key non-alcoholic steatohepatitis patient populations covering 171 countries…
The number of diagnosed prevalent cases of SCA in the countries under study will increase by 10% over the 20-year forecast period, from 29,000 to 32,000. Of the countries considered in this…